

# PPU COUNSELS FARMACÉUTICA EUROANDINA ON ACQUISITION OF HERSIL

*Posted on 7 November 2022*



**Category:** [Deal & transactions](#)

**Tags:** [acquisition](#), [cn2](#), [Guillermo Ferrero](#), [M&A](#), [Miranda & Amado](#), [Peru](#), [Pharmaceutical](#), [PPU](#), [Roberto MacLean](#), [sale of shares](#)



Philippi Prietocarrizosa Ferrero DU & Uría has counselled Farmacéutica Euroandina, a subsidiary of the pharmaceutical laboratory Medifarma, on the acquisition of 100% of the common shares of HERSIL Laboratorios Industriales Farmacéuticos (Pharmaceutical Industrial Laboratories).

This transaction, signed in November 2021 and closed in October 2022, was approved by the Antitrust Authority, and involved Farmacéutica Euroandina requesting approval from the Peruvian Competition Authority (INDECOPI) prior to closing due to new merger control regulations in Peru.

The advisory consisted of a due diligence and negotiation process that underwent exhaustive monitoring, in order to avoid non-compliance with similar anti-trust regulation and arms-length policies. The transaction was assessed in Phase 2 of the merger control procedure, the first ever in such a position in Peru.

HERSIL's shareholders, the sellers, were advised by Miranda & Amado.

**Connie Univazo** acted as in-house counsel for Farmacéutica Euroandina.

Miranda & Amado's team included partners **Roberto MacLean**, **Enrique Felices**, **Fiorella Zumaeta** and **Pablo Sotomayor**, together with associates **Mariano Perú**, **Luis Miguel Sánchez** and **Alejandra Quintanilla**.

PPU's team was led by partner **Guillermo Ferrero** (pictures left), with support from principal associate **Víctor Abad** (pictured right) and senior associate **José Salgado**. **Verónica Vergaray** and **Ximena del Rosario** provided antitrust advice.